Sign in
Taking peopleNo phase

Home walking program with activity tracker compared to supervised exercise for peripheral artery disease

Compares tracker-guided home exercise with supervised exercise in people with symptomatic peripheral artery disease.

Key facts

Who runs it
Chinese University of Hong Kong
Where
Hong Kong1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Improving Walking Performance in Patients With Peripheral Artery Disease Through Wearable Activity Trackers
Status
Recruiting
People taking part
70 people, planned
Started
1 Jun 2025
Expected to end
29 Feb 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • supervised exercise therapy (SET)
  • Wearable activities monitor (WAM)
  • enhanced HBET
  • Mobile application
Record updated
10 June 2025

Who can take part

The trial is looking for people newly diagnosed with peripheral artery disease who have leg pain when walking (claudication). The main target is people with an ABI below 0.9.

Sex
All sexes can join.
Disease stage
Newly diagnosed peripheral artery disease with claudication symptoms (leg pain when walking), found with a single claudication question.
Earlier treatment
People who already had a procedure or surgery to reopen the leg arteries cannot join.
Biomarker or test result
ABI (ankle-brachial index, a blood pressure test comparing ankle and arm) below 0.9 is the main target.
Main reasons for not taking part
  • Cannot walk without walking aids, or cannot understand exercise instructions
  • Critical limb ischemia (severe lack of blood flow to the leg), gangrene, or major leg amputation
  • Unstable heart problems such as unstable angina, acute coronary syndrome, or active class III/IV heart failure
  • Cannot use simple electronic devices or has no mobile network at home
  • Life expectancy less than 6 months, or other illnesses that limit walking
Show the full registry criteria (13)Hide the full registry criteria

Who can take part

  • Patients who are newly diagnosed with symptomatic claudication as defined by the presence of claudication symptoms elicited by the single claudication question
  • Patients who ABI <0.9 are the primary target population

Who cannot take part

  • Patients have history of previous percutaneous or surgical revascularization of lower limb
  • Patients has history of major amputation of the lower limb
  • Patients is presence of cardiovascular instability which includes unstable angina or acute coronary syndrome
  • Patients diagnosed active class III/IV heart failure
  • Patients is inability to ambulate without walking aids or understand the instruction of exercise
  • Patients is presence of critical limb ischemia or gangrene
  • Patients is presence of other co-morbidities which limit walking ability
  • Patients is inability to operate simple electronic devices
  • Patients is inaccessibility of a mobile network service in the place of residence
  • Patients is unwillingness in sharing individual data to study team
  • Patients is life-expectance less than 6 months

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Peripheral artery disease

This trial is currently available in Hong Kong.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Peripheral Arterial Disease (PAD) of the lower extremities is common and prevalence of PAD is increasing in our aging population. The presence of PAD is associated with increased cardiovascular morbidity and mortality, reduced physical function and quality of life.

Read full original descriptionShow less

Intermittent claudication is the most common symptom of PAD affecting about 30% of the patients. Supervised exercise therapy (SET) is safe and cost-effective therapy when compared with invasive revascularization, and is recommended as the first-line treatment for symptomatic PAD. However, SET is not readily available in the public healthcare system.

Barriers to SET implementation include demands for healthcare resources and the inconvenience of travelling to designated centre for SET. Home-based exercise therapy (HBET) has been proposed as an alternative to SET as they are more accessible and more acceptable to patients, but the benefits of HBET compared to SET have not been consistently demonstrated in studies. Wearable activities monitor (WAM) have been proposed as an adjuvant to enhance the performance of HBET. However, there is no direct comparison of WAM enhanced HBET to SET. Furthermore, WAMs were mainly used for monitoring in HBET in the previous studies and patient feedback was conducted either in-person or over telephones by the researchers, which challenges the true meaning of HBET. In this study, we aim to evaluate the non-inferiority of personalized self-guided HBET enhanced with WAM and auto feedback mobile apps, to SET, in a randomized-controlled trial of patients with symptomatic PAD.

The 2 groups in the trial

  • SETExisting treatment, for comparison

    Supervised exercise therapy (SET) is The supervised program is conducted at the research institute under the supervision of a qualified healthcare provider. It consists of 12 weeks of intermittent treadmill walking to moderate to severe claudication pain at a speed of ≈2 mph. WAM will be offered to both intervention and control arms, but the mobile apps will only be installed for the subjects randomized to intervention arm. All subjects will receive from their physicians, according to the guidelines, cardiovascular risk management, cholesterol-lowering medication, antiplatelet therapy, the advice to stop smoking, and modification of other atherosclerotic risk factors that were present5. All borrowed devices will be returned at the end of the study.

    Treatment: supervised exercise therapy (SET), Wearable activities monitor (WAM), and Mobile application

  • eHBETTreatment being tested

    eHBET enhanced with Wearable Activities Monitor (WAM), and an app-based program installed on their mobile device that provides personalized auto-feedback based on their level of activities and lifestyle (treatment). Patients who are already using a smartwatch capable of the steps count and activity monitor before this study are allowed to use their own devices but are encouraged to switch to the FitBit watch for uniformity of data collection. Patients will be encouraged to wear the watch as often as possible during daytime and during sleep. Data gathered will be automatically transmitted wirelessly to a cloud-based platform provided by the manufacturer. The data from the WAM will be extracted and integrated to the mobile apps, accessible only by the research team and the patient. During the randomization visit, patients will be given simple instructions on how to operate the device and how to connect the device to the mobile apps.

    Treatment: Wearable activities monitor (WAM), enhanced HBET, and Mobile application

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Impact of Wearable Activity Linked Kinetic Therapy on the Walking Performance and Vascular Health in Patients With Peripheral Artery Disease: A Randomized Clinical Trial (the WALK-PAD Trial)
Plain-language title
Home walking program with activity tracker compared to supervised exercise for peripheral artery diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT07012070, who can take part
Record updated
10 June 2025